By Lars Mucklejohn Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital’s beleaguered bourse. The FTSE 250 drugmaker said it had received “strong indications of support” from its shareholders for the move. Under the plan, which will be put to a shareholder vote next month, Indivior would maintain a secondary listing in the UK. Indivior, which was spun out of consumer health and hygiene giant Reckitt Benckiser in 2014, established a secondary listing on the Nasdaq last year…